GluN2B-Selective NMDAR Antagonists With Acidic-pH Potency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GluN2B-selective NMDAR antagonists lack clinical efficacy and have unacceptable side effects, and there is a need for compounds with enhanced potency at acidic pH to treat CNS conditions.
Innovation Solution
Development of negative allosteric modulators that selectively inhibit GluN2B-containing NMDARs, with increased potency at acidic pH, targeting GluN2B over GluN2A, GluN2C, and/or GluN2D subunits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If GluN2B-selective NMDAR antagonists are used, then selectivity for GluN2B subunit is improved, but clinical efficacy is poor and side effects are unacceptable
Solution Approach 1:
The patent modifies the pharmacological parameters of GluN2B-selective antagonists by introducing pH-dependent binding characteristics. The compounds are designed to have enhanced affinity and potency specifically at acidic pH (e.g., pH 6.5-7.0), which corresponds to the microenvironment of activated NMDARs during pathological conditions. This parameter change enables the antagonists to achieve effective blocking of GluN2B-containing NMDARs in vivo while maintaining safety profile.
Solution Approach 2:
The patent employs pH as an intermediary mechanism to bridge the gap between in vitro selectivity and in vivo efficacy. By designing compounds that utilize pH-dependent binding, the acidic microenvironment of activated NMDARs serves as a mediator that enhances drug-receptor interaction specifically at the site of pathology, thereby improving clinical efficacy without requiring non-specific binding.
2Reliability
If NMDAR antagonists are used to inhibit overactivated NMDARs, then neuroprotection is improved, but side effects are unacceptable
Solution Approach 1:
The patent applies local quality by designing NMDAR antagonists with pH-dependent binding characteristics that are specifically activated in acidic microenvironments. This ensures that the neuroprotective effect is localized to areas of pathology (ischemia, stroke, TBI) where acidification occurs, while normal brain tissue with physiological pH remains unaffected, thereby reducing system-wide side effects.
Solution Approach 2:
The patent introduces dynamic pH-dependent binding to the NMDAR antagonists, allowing the drug-receptor interaction to be modulated by the local pH environment. The compounds dynamically adjust their binding affinity based on the pH gradient between healthy and injured tissue, providing neuroprotection where needed while minimizing adverse effects in normal tissue.
3Reliability
If GluN2B-selective antagonists are developed, then preclinical efficacy is improved, but translation to clinical success fails
Solution Approach 1:
The patent addresses the translation gap by modifying the pharmacological parameters of GluN2B-selective antagonists to incorporate pH-dependent binding. This parameter change enables the compounds to achieve effective concentrations and binding affinity in the acidic microenvironment of activated NMDARs during clinical conditions, thereby bridging the gap between preclinical models and clinical applications.
Solution Approach 2:
The patent replaces the conventional pH-independent binding mechanism with a pH-dependent binding mechanism that leverages the natural acidification of the extracellular space during pathology. This substitution of binding mechanism allows the antagonists to be activated specifically at sites of injury, improving translational efficacy without requiring additional delivery systems or modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modulators provide improved neuroprotection in CNS conditions by reducing neuronal death and alleviating symptoms such as pain, depression, and stroke, with enhanced efficacy at acidic pH.
Implementation Method 1
the modulators possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH
Data Source
AI summary
Compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM/DARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and/or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.